Last updated on June 2019

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Brief description of study

This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters

Clinical Study Identifier: NCT02962895

Find a site near you

Start Over

Novartis Investigative Site

Itabashi-ku, Japan
  Connect »

Novartis Investigative Site

Shinjuku-ku, Japan
  Connect »